Visit the new website -
Our Corporate Responsibility 2012 online
Our Corporate Responsibility 2012
At CSL, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities. We believe that behaving responsibly is critical to the sustainability of our company.
We align CR with our business goals and ensure that it complements our unique capabilities and benefits our diverse set of stakeholders.
Our Corporate Responsibility Priority Areas
Researching and developing new medicines for unmet needs, while continually improving our protein-based therapies for patients;
Ensuring our therapies are safe and of the highest quality by maintaining the highest standards throughout all stages of the product life cycle;
Operating responsibly in the marketplace by marketing our medicines in an ethical manner, working with others to improve equity of access and sharing our financial success;
Providing a positive working environment for our people by engendering a culture of mutual trust and respect, enabling them to do their jobs safely and effectively, and rewarding and recognising their contributions;
Supporting our patient, biomedical and local communities by improving access to our therapies and enhancing the quality of life for patients, advancing scientific knowledge and supporting future medical researchers, and engaging our staff in the support of local communities; and
Minimising our impacts on the environment through the responsible management of our operations and natural resources, without compromising the safety, quality and accessibility of our therapies.
Our values form the foundation of CSL’s global commitment to CR. Our
Code of Responsible Business Practice further guides and shapes the way we do business. It defines our ethical standards and sets out our commitment to sustainable development.
In 2009, CSL established a Corporate Responsibility Steering Committee to facilitate the development of our CR priorities and to drive awareness, integration and continuous improvement of CR throughout the Company. The Committee reports to the CEO/ Managing Director and is further supported by the Board’s five committees which share accountability for corporate responsibility issues.
We regard stakeholder engagement as a foundation of corporate responsibility, and have identified our key stakeholders as patient groups, employees, investors, regulators, suppliers, government, healthcare professionals, plasma donors, business partners and the academic and scientific community.
Stakeholder engagement covers many different activities from the provision of information and educational material to health service providers, through to active collaboration with and support of patient organisations and structured dialogue with stakeholder representatives.
Our Corporate Responsibility 2011
GRI Index 2011
Our Corporate Responsibility 2010
GRI Index 2010
Our Corporate Responsibility 2009
GRI Index 2009